Lv43
706 积分 2020-08-09 加入
Importing oncology trials from China: a bridge over troubled waters?
1小时前
已完结
Innovative antibody therapeutic development in China compared with the USA and Europe
3天前
已完结
GenSci120, a humanized PD-1 agonistic monoclonal antibody, enhances the binding of both PD-L1 and PD-L2 to PD-1, and mitigates the symptoms of GVHD in a mouse model
4天前
已完结
Small-molecule control of CAR T cells
6天前
已完结
Past, present and future of drug conjugates for cancer therapy
8天前
已完结
RGN6024 is a brain-penetrant, small molecule tubulin destabilizer for the treatment of glioblastoma
13天前
已完结
SDP-LIV1, a Novel and Optimized LIV-1 Antibody-drug Conjugate Demonstrating Superior Anti-Tumor Efficacy and Favorable Safety Profile for Treatment of Solid Tumors
15天前
已完结
Trends in gene therapy delivery technologies
15天前
已完结
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China
20天前
已完结
BCMA T-Cell Engager Therapy in Patients with Refractory Autoimmune Disease
26天前
已完结
皖公网安备34019202002308
